Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III

Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III

Background. Neoadjuvant chemotherapy (NACT) with dual anti-HER2 blockade has become a priority in the treatment of patients with HER2+ breast cancer (BC) stages IIIII. However, the question of the accordance of various systems for assessing tumor response to NACT, as well as identifying predictor fa...

Full description

Bibliographic Details
Main Authors:	Dmitriy A. Morozov, Irina V. Kolyadina, Irina V. Poddubnaya, Inna P. Ganshina, Svetlana V. Khokhlova, Vlada V. Kоmetova, Valery V. Rodionov
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2021-12-01
Series:	Современная онкология
Subjects:	her2+ breast cancer stage ii–iii neoadjuvant chemotherapy dual anti-her2 blockade (trastuzumab + pertuzumab) pcr rcb residual pathomorphological stage yptn tils predictor factors for achieving pcr
Online Access:	https://modernonco.orscience.ru/1815-1434/article/viewFile/100046/73603

Similar Items

Clinical and morphological aspects of neoadjuvant chemotherapy efficacy in patients with aggressive luminal HER2-negative breast cancer
by: D. A. Morozov, et al.
Published: (2022-01-01)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
by: Babak Nami, et al.
Published: (2019-03-01)

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
by: Babak Nami, et al.
Published: (2018-09-01)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain
by: Victor L. Cruz, et al.
Published: (2023-07-01)

Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines
by: Marta Sanz-Álvarez, et al.
Published: (2023-12-01)

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials
by: Xiaoyun Liu, et al.
Published: (2022-09-01)

A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
by: Dongdong Xu, et al.
Published: (2024-02-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer
by: Thibaut Sanglier, et al.
Published: (2022-05-01)

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status
by: Azzurra Irelli, et al.
Published: (2022-06-01)

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
by: Shuhui You, et al.
Published: (2023-12-01)

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
by: Francesca Ligorio, et al.
Published: (2021-04-01)

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
by: Sanne L. de Haas, et al.
Published: (2023-01-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

Therapeutic Response Monitoring with <sup>89</sup>Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
by: Minwoo Kang, et al.
Published: (2022-06-01)

Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression
by: Amélie Aboudaram, et al.
Published: (2021-09-01)

Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
by: Sandhya Mehta, et al.
Published: (2023-09-01)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
by: Chau Dang, et al.
Published: (2022-05-01)

Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer
by: M. A. Frolova, et al.
Published: (2021-12-01)

Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study
by: Agnese Fabbri, et al.
Published: (2023-06-01)

Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer
by: Azzurra Irelli, et al.
Published: (2024-01-01)

Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer
by: E. V. Lubennikova, et al.
Published: (2021-12-01)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01)

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer
by: Emma Franco-Mateos, et al.
Published: (2024-04-01)

Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression
by: Hans Wildiers, et al.
Published: (2022-08-01)

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
by: Daniel Rayson, et al.
Published: (2022-12-01)

Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy
by: E V Artamonova, et al.
Published: (2015-06-01)

Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligands
by: Devin L. Wakefield, et al.
Published: (2023-04-01)

Evolving Treatment Landscape of <i>HER2</i>-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
by: Ioannis A. Vathiotis, et al.
Published: (2023-02-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01)

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
by: Sofia Batalha, et al.
Published: (2023-10-01)

Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba
by: Elías A. Gracia Medina, et al.
Published: (2023-01-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact?
by: Mirela Gherghe, et al.
Published: (2022-12-01)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
by: Laura L. Michel, et al.
Published: (2020-10-01)

Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer
by: V. A. Kostorov, et al.
Published: (2018-07-01)

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy
by: Alexey Goltsov, et al.
Published: (2014-06-01)

Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
by: Anshul Gupta, et al.
Published: (2023-01-01)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01)